Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry
Abstract Biologic and targeted synthetic disease-modifying antirheumatic drugs (ts/bDMARDs) play a pivotal role in the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). Persistence of therapy provides an index of a drug’s overall effectiveness. The o...
Main Authors: | A. Prior-Español, C. Sánchez-Piedra, J. Campos, F. J. Manero, C. Pérez-García, C. Bohórquez, N. Busquets-Pérez, J. M. Blanco-Madrigal, C. Díaz-Torne, F. Sánchez-Alonso, L. Mateo, S. Holgado-Pérez |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-05-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-90442-w |
Similar Items
-
HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?
by: Gerd Burmester, et al.
Published: (2020-05-01) -
Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years
by: Carlos Sánchez-Piedra, et al.
Published: (2021-07-01) -
Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register
by: Paloma Vela, et al.
Published: (2020-06-01) -
bDMARDs retention rate in the biosimilar era: A real-life monocentric study
by: Andrea Becciolini, et al.
Published: (2021-04-01) -
Data from the Romanian Registry of Rheumatic Diseases (RRBR) for patients with axial spondyloarthritis treated with biologic disease-modifying anti-rheumatic drugs (bDMARDs) during 2019
by: Ruxandra Ionescu, et al.
Published: (2020-03-01)